“PROTAC 6”

IAP-based selective RIPK2 degrader

prolonged PD w/ 0.15 mpk SC Q3D dosing

E3 binder switch and property-based opt.

Commun. Biol., Mar. 20, 2020

GlaxoSmithKline, Stevenage, UK / PMCC

“PROTAC 6” (GlaxoSmithKline (GSK) IAP-based selective RIPK2 degrader with prolonged in vivo PD)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.